Mesoblast (ASX:MSB) Shiller PE Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MSB Mesoblast Ltd ASX:MSB
39 GF Score
Price A$2.37
! 4 Warning Signs
View Full Analysis

What is Mesoblast Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mesoblast  (ASX:MSB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Mesoblast Shiller PE Ratio Related Terms


Mesoblast Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Mesoblast's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Shiller PE Ratio Chart

Mesoblast Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Mesoblast Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:MSB vs VRTX, REGN, RVMD: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Mesoblast's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Mesoblast's Shiller PE Ratio falls into.


ASX:MSB
39GF Score
Mesoblast Ltd ASX:MSB
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Mesoblast's E10 for the quarter that ended in Mar. 2026 is calculated as:

For example, Mesoblast's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/137.0353*137.0353
=0.000

Current CPI (Mar. 2026) = 137.0353.

Mesoblast Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201606 0.173 0.000
201609 -0.065 0.000
201612 -0.067 0.000
201703 -0.030 0.000
201706 -0.079 0.000
201709 -0.019 0.000
201712 0.036 0.000
201803 -0.055 0.000
201806 -0.056 0.000
201809 -0.054 0.000
201812 -0.066 0.000
201903 -0.067 0.000
201906 -0.057 0.000
201909 -0.015 0.000
201912 -0.063 0.000
202003 -0.043 0.000
202006 -0.084 0.000
202009 -0.055 0.000
202012 -0.055 0.000
202103 -0.054 0.000
202106 -0.041 0.000
202109 -0.045 0.000
202112 -0.053 0.000
202203 -4.217 0.000
202206 -4.495 0.000
202209 -0.035 0.000
202212 -0.047 0.000
202303 -3.593 0.000
202306 11.555 0.000
202309 0.000 0.000
202312 0.000 0.000
202403 0.000 0.000
202406 0.000 0.000
202409 0.000 129.143 0.000
202412 0.000 130.173 0.000
202503 0.000 131.042 0.000
202506 0.000 131.551 0.000
202509 0.000 133.771 0.000
202512 0.000 135.069 0.000
202603 0.000 137.035 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
39GF Score

Get the complete analysis for ASX:MSB

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.37
Price